Recent blog posts
NCT07691593 HRS-4642 Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07691593 HRS-4642 Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07691593 clinical trial report covering HRS-4642, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07693452 Metformin Pseudomyxoma Peritonei Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07693452 Metformin Pseudomyxoma Peritonei Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07693452 clinical trial report covering Metformin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07691632 Serplulimab Adenocarcinoma of large intestine Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07691632 Serplulimab Adenocarcinoma of large intestine Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07691632 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07694336 Mepacrine hydrochloride Lupus Erythematosus, Discoid Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07694336 Mepacrine hydrochloride Lupus Erythematosus, Discoid Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07694336 clinical trial report covering Mepacrine hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07691762 Adebrelimab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07691762 Adebrelimab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07691762 clinical trial report covering Adebrelimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07692204 SAR-445877 Esophageal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07692204 SAR-445877 Esophageal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07692204 clinical trial report covering SAR-445877, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07692399 Edaravone/Dexborneol Blood brain barrier defect Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07692399 Edaravone/Dexborneol Blood brain barrier defect Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07692399 clinical trial report covering Edaravone/Dexborneol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
JPRN-jRCT2073260037 Invimestrocel (Athersys) Hypoxic respiratory failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2073260037 Invimestrocel (Athersys) Hypoxic respiratory failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
JPRN-jRCT2073260037 clinical trial report covering Invimestrocel (Athersys), Phase 3, endpoints, sponsor, geography, readout timing and development white spac
Read →
NCT07695597 SYH2070 Mixed hyperlipidemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07695597 SYH2070 Mixed hyperlipidemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07695597 clinical trial report covering SYH2070, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
JPRN-jRCT2041260085 Efimosfermin alfa Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2041260085 Efimosfermin alfa Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
JPRN-jRCT2041260085 clinical trial report covering Efimosfermin alfa, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
JPRN-jRCT2041260084 Efimosfermin alfa Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2041260084 Efimosfermin alfa Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
JPRN-jRCT2041260084 clinical trial report covering Efimosfermin alfa, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07695285 Lemborexant Emergence Delirium Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07695285 Lemborexant Emergence Delirium Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07695285 clinical trial report covering Lemborexant, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →